

Ian J Clifton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7065413/publications.pdf>

Version: 2024-02-01

47
papers

873
citations

567281

15
h-index

477307

29
g-index

47
all docs

47
docs citations

47
times ranked

1487
citing authors

#	ARTICLE	IF	CITATIONS
1	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research, 2016, 2, 00081-2015.	2.6	133
2	Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Review of Respiratory Medicine, 2012, 6, 91-103.	2.5	107
3	Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technology Assessment, 2013, 17, 1-342.	2.8	75
4	Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. ELife, 2020, 9, .	6.0	75
5	Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open, 2016, 6, e011857.	1.9	61
6	Development of an integrated rehabilitation pathway for individuals recovering from COVID-19 in the community. Journal of Rehabilitation Medicine, 2020, 52, jrm00089.	1.1	54
7	Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: Before, during and after treatment with intravenous antibiotics. Journal of Cystic Fibrosis, 2007, 6, 67-73.	0.7	39
8	Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention. Journal of Cystic Fibrosis, 2009, 8, 179-185.	0.7	39
9	Defining routes of airborne transmission of <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis. Expert Review of Respiratory Medicine, 2010, 4, 519-529.	2.5	37
10	A laminar flow model of aerosol survival of epidemic and non-epidemic strains of <i>Pseudomonas aeruginosa</i> isolated from people with cystic fibrosis. BMC Microbiology, 2008, 8, 105.	3.3	24
11	Use of ceftazidime/avibactam for the treatment of MDR <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> complex infections in cystic fibrosis: a case series. Journal of Antimicrobial Chemotherapy, 2019, 74, 1425-1429.	3.0	23
12	An aerobiological model of aerosol survival of different strains of <i>Pseudomonas aeruginosa</i> isolated from people with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 64-68.	0.7	21
13	Level of accuracy of diagnoses recorded in discharge summaries: A cohort study in three respiratory wards. Journal of Evaluation in Clinical Practice, 2019, 25, 36-43.	1.8	21
14	Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiology and Infection, 2008, 136, 128-134.	2.1	20
15	The impact of three discharge coding methods on the accuracy of diagnostic coding and hospital reimbursement for inpatient medical care. International Journal of Medical Informatics, 2018, 115, 35-42.	3.3	17
16	Survival of <i>Mycobacterium abscessus</i> isolated from people with cystic fibrosis in artificially generated aerosols. European Respiratory Journal, 2016, 48, 1789-1791.	6.7	14
17	Bronchial Artery Embolisation for Massive Haemoptysis: Immediate and Long-Term Outcomes – A Retrospective Study. Pulmonary Therapy, 2020, 6, 107-117.	2.2	14
18	Acute <i>Burkholderia cenocepacia</i> pyomyositis in a patient with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 273-275.	0.7	11

#	ARTICLE	IF	CITATIONS
19	The Role of Nursing Activities on the Bioaerosol Production in Hospital Wards. <i>Indoor and Built Environment</i> , 2013, 22, 410-421.	2.8	11
20	Cytomegalovirus Pneumonia in an Immunocompetent Adult: A Case Report. <i>Acute Medicine</i> , 2011, 10, 197-199.	0.3	10
21	Modeling fomite-mediated SARS-CoV-2 exposure through personal protective equipment doffing in a hospital environment. <i>Indoor Air</i> , 2022, 32, .	4.3	10
22	Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2438-2440.	3.0	9
23	Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure. <i>Journal of Cystic Fibrosis</i> , 2004, 3, 273-275.	0.7	7
24	Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 82-87.	2.6	6
25	Noninvasive Ventilation in Cystic Fibrosis: Clinical Indications and Outcomes in a Large UK Adult Cystic Fibrosis Center. <i>Respiratory Care</i> , 2021, 66, 466-474.	1.6	6
26	Effects of patient room layout on viral accrue ment on healthcare professionals' hands. <i>Indoor Air</i> , 2021, 31, 1657-1672.	4.3	5
27	Ward based inhaler technique service reduces exacerbations of asthma and COPD. <i>Respiratory Medicine</i> , 2021, 187, 106583.	2.9	5
28	Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis. <i>ERJ Open Research</i> , 2022, 8, 00669-2021.	2.6	4
29	Breathlessness in palliative care: a practical guide. <i>British Journal of Hospital Medicine (London,)</i> Tj ETQq1 1 0.784314 rgBT /Qverlock 10 0.5 /3		
30	Concurrent pulmonary zygomycosis and Mycobacterium tuberculosis infection: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 17.	0.8	2
31	An unusual cause of hypercalcaemia in a patient with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2007, 6, 369-370.	0.7	2
32	No lung cancer at resection of PET positive lesions: an audit of the lung cancer multidisciplinary team. <i>European Respiratory Journal</i> , 2009, 33, 941-942.	6.7	2
33	Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis. <i>ERJ Open Research</i> , 2018, 4, 00111-2017.	2.6	2
34	The Effect of Sub-MIC ² -Lactam Antibiotic Exposure of <i>Pseudomonas aeruginosa</i> Strains from People with Cystic Fibrosis in a Desiccation Survival Model. <i>International Journal of Microbiology</i> , 2011, 2011, 1-6.	2.3	1
35	Improving end-of-life communication between primary and secondary care within respiratory medicine. <i>European Respiratory Journal</i> , 2016, 47, 658-660.	6.7	1
36	Nasal high-flow therapy as an adjunct to exercise in patients with cystic fibrosis: A pilot feasibility trial. <i>Journal of Cystic Fibrosis</i> , 2021, 20, e46-e52.	0.7	1

#	ARTICLE	IF	CITATIONS
37	Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB) - a cross sectional study. <i>Clinical Nutrition</i> , 2021, 40, 5162-5168.	5.0	1
38	Nobody Does it Better: A Patient Physician Perspective of Asthma Management. <i>Pulmonary Therapy</i> , 2019, 5, 5-10.	2.2	0
39	Integrating CFD and exposure modeling for estimating viral exposures at the air-surface interface. , 2021, , .		0
40	Emergency department (ED) attendance with asthma: An unmet need for specialist review. , 2016, , .		0
41	Adrenal insufficiency in asthma patients – Who is at risk?. , 2016, , .		0
42	Emergency asthma care in England: Themes identified during audits at five hospital trusts. , 2016, , .		0
43	A new score to identify patients who need fitness to fly test. , 2018, , .		0
44	Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre. , 2019, , .		0
45	Do CT findings of Mycobacterium abscessus infection in patients with Cystic Fibrosis predict outcome?. , 2019, , .		0
46	Outcomes at 6 months following NIV in adults with cystic fibrosis (CF): experience of a large UK centre. , 2019, , .		0
47	The impact of a specialist physiotherapist in the Leeds difficult asthma service. , 2019, , .		0